4.7 Review

Modulation of Androgen Receptor by FOXA1 and FOXO1 Factors in Prostate Cancer

Journal

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
Volume 10, Issue 6, Pages 614-619

Publisher

IVYSPRING INT PUBL
DOI: 10.7150/ijbs.8389

Keywords

Androgens; androgen receptor; FOXA1; prostate cancer

Ask authors/readers for more resources

Androgens and the androgen receptor (AR) are essential for growth and differentiation of the normal prostate gland as well as proliferation and survival of prostate cancer (PCa). Increasing evidence suggests that reactivation of the AR plays a pivotal role in disease progression to castration-resistant PCa (CRPC). Forkhead box (FOX) factors exert two distinct effects on AR function in PCa. The A-class of FOX proteins, especially FOXA1, functions as a pioneer factor to facilitate AR transactivation and PCa growth. In contrast, the O-class of FOX proteins such as FOXO1 and FOXO3, which are downstream effectors of the PTEN tumor suppressor, inhibit the transcriptional activity of either full-length AR or constitutively active splice variants of AR in a direct or indirect manner in PCa. FOXO1 also contributes to taxane-mediated inhibition of the AR and CRPC growth. Therefore, FOX family members not only have a tight relationship with AR, but also represent a pivotal group of proteins to be targeted for PCa therapy. The present review focuses primarily on recent advances in the epigenetic, mechanistic and clinical relevant aspects of regulation of the AR by FOXA1 and FOXO1 factors in PCa.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemistry & Molecular Biology

LSD1 promotes S-phase entry and tumorigenesis via chromatin co-occupation with E2F1 and selective H3K9 demethylation

Y. He, Y. Zhao, L. Wang, L. R. Bohrer, Y. Pan, H. Huang

ONCOGENE (2018)

Article Multidisciplinary Sciences

Cyclophilin J limits inflammation through the blockage of ubiquitin chain sensing

Chunjie Sheng, Chen Yao, Ziyang Wang, Hongyuan Chen, Yu Zhao, Dazhi Xu, Haojie Huang, Wenlin Huang, Shuai Chen

NATURE COMMUNICATIONS (2018)

Article Biochemistry & Molecular Biology

EZH2 cooperates with gain-of-function p53 mutants to promote cancer growth and metastasis

Yu Zhao, Liya Ding, Dejie Wane, Zhenqing Ye, Yundong He, Linlin Ma, Runzhi Zhu, Yunqian Pan, Qiang Wu, Kun Pang, Xiaonan Hou, Saravut J. Weroha, Conghui Han, Roger Coleman, Ilsa Coleman, R. Jeffery Karnes, Jun Zhang, Peter S. Nelson, Liguo Wang, Haojie Huang

EMBO JOURNAL (2019)

Article Medicine, Research & Experimental

The novel BET-CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer

Yuqian Yan, Jian Ma, Dejie Wang, Dong Lin, Xiaodong Pang, Shangqian Wang, Yu Zhao, Lei Shi, Hui Xue, Yunqian Pan, Jun Zhang, Claes Wahlestedt, Francis J. Giles, Yu Chen, Martin E. Gleave, Collin C. Collins, Dingwei Ye, Yuzhuo Wang, Haojie Huang

EMBO MOLECULAR MEDICINE (2019)

Article Biochemistry & Molecular Biology

Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine

Simeng Wen, Yulei Wei, Chong Zen, Wei Xiong, Yuanjie Niu, Yu Zhao

MOLECULAR CANCER (2020)

Article Oncology

Downregulation of SHMT2 promotes the prostate cancer proliferation and metastasis by inducing epithelial-mesenchymal transition

Lei Chen, Hailong Liu, Yiyi Ji, Zehua Ma, Kai Shen, Xun Shangguan, Hongyang Qian, Yu Zhao, Chun-Wu Pan, Wei Xue

Summary: The study reveals that SHMT2 plays a role as a tumor proliferation suppressor and negatively regulates aggressive behavior in prostate cancer. Downregulation of SHMT2 is observed in advanced prostate cancer, and its depletion promotes proliferation and migration in prostate cancer cell lines. These findings highlight the importance of SHMT2 in prostate cancer and its potential for the development of new therapeutic strategies.

EXPERIMENTAL CELL RESEARCH (2022)

Article Multidisciplinary Sciences

A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer

Nan Niu, Fang Qiu, Qianshi Xu, Guijin He, Xi Gu, Wenbin Guo, Dianlong Zhang, Zhigao Li, Yi Zhao, Yong Li, Ke Li, Hao Zhang, Peili Zhang, Yuanxi Huang, Gangling Zhang, Hongbin Han, Zhengang Cai, Pengfei Li, Hong Xu, Guanglei Chen, Jinqi Xue, Xiaofan Jiang, Alireza Hamidian Jahromi, Jinshi Li, Yu Zhao, Eduardo de Faria Castro Fleury, Shiwen Huo, Huajun Li, Guy Jerusalem, Domenico Tripodi, Tong Liu, Xinyu Zheng, Caigang Liu

Summary: This study reports the results of an oral neoadjuvant therapy in treatment-naive patients with triple-positive breast cancer, showing positive clinical efficacy and safety with no serious adverse events or treatment-related deaths.

NATURE COMMUNICATIONS (2022)

Article Medicine, Research & Experimental

Enhancer RNA promotes resistance to radiotherapy in bone-metastatic prostate cancer by m6A modification

Yu Zhao, Simeng Wen, Hang Li, Chun-Wu Pan, Yulei Wei, Ting Huang, Zhaochen Li, Yinhui Yang, Saijun Fan, Yingyi Zhang

Summary: This study identified bone-specific m6A-modified eRNA as a novel predictor for radiotherapy resistance in bone metastatic prostate cancer (mPCa). The RNA-binding protein KHSRP was found to play a functional role in inhibiting RNA degradation, thus contributing to radiotherapy resistance. Inhibition of the MLXIPe/KHSRP/PSMD9 regulatory complex was shown to suppress tumor growth and sensitize mPCa to radiotherapy.

THERANOSTICS (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

PET imaging of new target CDK19 in prostate cancer

Dong Dai, Jiang Yu, Ting Huang, Yansheng Li, Ziyang Wang, Shuangmeng Yang, Shuai Li, Yanli Li, Wenfeng Gou, Deguan Li, Wenbin Hou, Saijun Fan, Yiliang Li, Yu Zhao

Summary: In this study, a novel tissue-specific gene CDK19 was found to be overexpressed in high-risk metastatic prostate cancer, and its expression correlated with metastatic status and tumor staging. Ga-68-CDK19 PET/CT was shown to be effective in detecting lesions with or without PSMA in vitro, in vivo, and in the PDX model. These findings suggest that Ga-68-CDK19 may be a predictive biomarker for PET scans in prospective cohorts and may help identify molecular types of prostate cancer independent of PSMA.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2023)

Article Chemistry, Multidisciplinary

Biomodified Extracellular Vesicles Remodel the Intestinal Microenvironment to Overcome Radiation Enteritis

Hang Li, Shuya Zhao, Mian Jiang, Tong Zhu, Jinjian Liu, Guoxing Feng, Lu Lu, Jiali Dong, Xin Wu, Xin Chen, Yu Zhao, Saijun Fan

Summary: This study found that exosomes derived from mice exposed to total body irradiation can protect recipient mice against radiation-induced gut injury. MiR-142, highly expressed in exosomes, plays a key role in mediating the protective effect against radiation enteritis by improving the intestinal microenvironment. Biomodification of exosomes through enhancing miR-142 expression and intestinal specificity can further improve the protection against radiation enteritis.

ACS NANO (2023)

Article Cell Biology

Nicotinamide riboside intervention alleviates hematopoietic system injury of ionizing radiation-induced premature aging mice

Wenxuan Li, Xinyue Wang, Yinping Dong, Qidong Huo, Tongpeng Yue, Xin Wu, Lu Lu, Junling Zhang, Yu Zhao, Hui Dong, Deguan Li

Summary: Radiotherapy induces premature aging effects in survivors, but effective methods for preventing this are lacking. This study evaluated the therapeutic effects of nicotinamide riboside on premature aging mice. The results showed that nicotinamide riboside treatment reversed aging phenotypes, improved serum metabolism, and restored the regenerative capacity of hematopoietic stem cells. These findings suggest that nicotinamide riboside has potential as a therapeutic agent for radiation-exposed populations and patients receiving radiotherapy.

AGING CELL (2023)

Article Medicine, Research & Experimental

KDM4 inhibitor SD49-7 attenuates leukemia stem cell via KDM4A/MDM2/p21CIPI axis

Yinghui Li, Chaoqun Wang, Huier Gao, Jiali Gu, Yiran Zhang, Yingyi Zhang, Min Xie, Xuelian Cheng, Ming Yang, Wenshan Zhang, Yafang Li, Mei He, Hui Xu, Hexiao Zhang, Qing Ji, Tianhua Ma, Sheng Ding, Yu Zhao, Yingdai Gao

Summary: This study identified a specific KDM4 inhibitor, SD49-7, for resistant leukemia therapy, demonstrating its ability to inhibit the progression of leukemia stem cells (LSCs) and overcome resistance to traditional treatments.

THERANOSTICS (2022)

Meeting Abstract Oncology

EFFICACY OF THE MDM2 INHIBITOR KRT-232 IN GLIOBLASTOMA PATIENT-DERIVED XENOGRAFT MODELS

Rachael Vaubel, Ann Mladek, Yu Zhao, Shiv K. Gupta, Minjee Kim, Afroz S. Mohammad, Katrina Bakken, Lihong He, Zeng Hu, Danielle M. Burgenske, Brett L. Carlson, William F. Elmquist, Jann Sarkaria

NEURO-ONCOLOGY (2020)

Meeting Abstract Oncology

INHIBITION OF DNA-PKCS BY M3814 POTENTIATES EFFICACY OF IONIZING RADIATION IN PATIENT-DERIVED XENOGRAFTS OF MELANOMA BRAIN METASTASES

Jianxiong Ji, Emily Smith, Paige Sarkaria, Ann Mladek, Surabhi Talele, Katelyn Swanson, Afroz S. Mohammad, Wenjuan Zhang, Lihong He, Zeng Hu, Yu Zhao, Jiajia Chen, Margaret A. Connors, Kendra A. Porath, Katrina K. Bakken, Sonja Dragojevic, Brett L. Carlson, Shiv K. Gupta, Danielle M. Burgenske, Gaspar J. Kitange, William F. Elmquist, Jann Sarkaria

NEURO-ONCOLOGY (2020)

Article Oncology

PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer

Yinhui Yang, Yang Bai, Yundong He, Yu Zhao, Jiaxiang Chen, Linlin Ma, Yunqian Pan, Michael Hinten, Jun Zhang, R. Jeffrey Karnes, Manish Kohli, Jennifer J. Westendorf, Benyi Li, Runzhi Zhu, Haojie Huang, Wanhai Xu

CLINICAL CANCER RESEARCH (2018)

No Data Available